$8.71
0.06[0.69%]
Last update: 10:44AM Get Real Time Here
Acrivon Therapeutics
(NASDAQ:ACRV)Acrivon Therapeutics Stock (NASDAQ:ACRV), Analyst Ratings, Price Targets, Predictions
Acrivon Therapeutics Inc has a consensus price target of $18.6, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from BMO Capital, HC Wainwright & Co., and Ladenburg Thalmann on May 15, 2024, May 14, 2024, and April 29, 2024. With an average price target of $15.67 between BMO Capital, HC Wainwright & Co., and Ladenburg Thalmann, there's an implied 81.12% upside for Acrivon Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
HC Wainwright & Co.
Ladenburg Thalmann
JMP Securities
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Acrivon Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/15/2024 | Buy Now | 189.02% | BMO Capital | Etzer Darout | $25 → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 05/14/2024 | Buy Now | 154.34% | HC Wainwright & Co. | Emily Bodnar | $20 → $22 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | — | Ladenburg Thalmann | Aydin Huseynov | — | Downgrade | Buy → Neutral | Get Alert |
| 04/26/2024 | Buy Now | 189.02% | BMO Capital | Etzer Darout | $18 → $25 | Maintains | Outperform | Get Alert |
| 04/25/2024 | Buy Now | 96.53% | JMP Securities | Silvan Tuerkcan | $14 → $17 | Maintains | Market Outperform | Get Alert |
| 04/25/2024 | Buy Now | 246.82% | Piper Sandler | Joseph Catanzaro | $26 → $30 | Maintains | Overweight | Get Alert |
| 04/25/2024 | Buy Now | 131.21% | HC Wainwright & Co. | Emily Bodnar | → $20 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | 61.85% | Ladenburg Thalmann | Aydin Huseynov | $18 → $14 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | 108.09% | BMO Capital | Etzer Darout | → $18 | Reiterates | Outperform → Outperform | Get Alert |
| 04/01/2024 | Buy Now | 61.85% | JMP Securities | Silvan Tuerkcan | → $14 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/28/2024 | Buy Now | 131.21% | HC Wainwright & Co. | Emily Bodnar | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 61.85% | JMP Securities | Silvan Tuerkcan | → $14 | Initiates | → Market Outperform | Get Alert |
| 11/10/2023 | Buy Now | 177.46% | BMO Capital | Etzer Darout | $25 → $24 | Maintains | Outperform | Get Alert |
| 10/05/2023 | Buy Now | 177.46% | Maxim Group | Michael Okunewitch | → $24 | Initiates | → Buy | Get Alert |
| 09/06/2023 | Buy Now | 131.21% | HC Wainwright & Co. | Emily Bodnar | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/18/2023 | Buy Now | 200.58% | JonesTrading | Soumit Roy | → $26 | Initiates | → Buy | Get Alert |
| 08/11/2023 | Buy Now | 131.21% | HC Wainwright & Co. | Emily Bodnar | $21 → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | Buy Now | 189.02% | Oppenheimer | Matthew Biegler | → $25 | Initiates | → Outperform | Get Alert |
| 05/08/2023 | Buy Now | 189.02% | BMO Capital | Etzer Darout | → $25 | Initiates | → Outperform | Get Alert |
| 05/02/2023 | Buy Now | 177.46% | HC Wainwright & Co. | Emily Bodnar | → $24 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | 177.46% | HC Wainwright & Co. | Emily Bodnar | → $24 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | — | Cowen & Co. | Joseph Thome | — | Initiates | → Outperform | Get Alert |
| 12/12/2022 | Buy Now | 96.53% | Jefferies | Akash Tewari | → $17 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | 189.02% | Piper Sandler | Joseph Catanzaro | → $25 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Acrivon Therapeutics (ACRV)?
The latest price target for Acrivon Therapeutics (NASDAQ: ACRV) was reported by BMO Capital on May 15, 2024. The analyst firm set a price target for $25.00 expecting ACRV to rise to within 12 months (a possible 187.03% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acrivon Therapeutics (ACRV)?
The latest analyst rating for Acrivon Therapeutics (NASDAQ: ACRV) was provided by BMO Capital, and Acrivon Therapeutics reiterated their outperform rating.
When was the last upgrade for Acrivon Therapeutics (ACRV)?
There is no last upgrade for Acrivon Therapeutics.
When was the last downgrade for Acrivon Therapeutics (ACRV)?
The last downgrade for Acrivon Therapeutics Inc happened on April 29, 2024 when Ladenburg Thalmann changed their price target from N/A to N/A for Acrivon Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Acrivon Therapeutics (ACRV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acrivon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acrivon Therapeutics was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.
Is the Analyst Rating Acrivon Therapeutics (ACRV) correct?
While ratings are subjective and will change, the latest Acrivon Therapeutics (ACRV) rating was a reiterated with a price target of $25.00 to $25.00. The current price Acrivon Therapeutics (ACRV) is trading at is $8.71, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.